Tumor lysate or carcinoembryonic antigen (CEA) derived DCs-based therapy is safe and can
elicites remarkable T-cell responses but mostly did not really transfer into significant
clinical benefit. One possible reason is the lack of effective antigen and the
immunosuppressive microenvironment. Now we are exploring another new strategy, prediction of
neoantigen for priming DCs as cell-based therapy with or without booster of
anti-VEGF/anti-PD-1.